The first story highlights coming clinical data on three prescription weight-loss therapies in development by separate small pharmaceutical companies. The second story details a small drug developer's effort to successfully find a treatment for lupus, a devastating autoimmune disease that hasn't had a new drug therapy in decades. The third story shows that Biogen Idec, a pharmaceutical company specializing in multiple sclerosis treatments, is walking on thin ice by deciding to not disclose new cases of a rare brain infection in patients using one of its prominent drugs. The fourth story is closely connected to the first: After finding success in late-stage clinical trials for their weight-loss therapies, three drug developers are looking to find large pharmaceutical companies to help them sell the potential blockbuster drugs.
See the contest questionnaire in which the reporter writes about how this story was written.
